Almirall S.A (LBTSF PINK) stock market data APIs
$15.466
0(0%)
as of February 4, 2026
Try our APIs with
free plan!
Almirall S.A Financial Data Overview
Price chart is built with
Anychart
Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, nervous, and respiratory system; dermatologicals; genito urinary system and sex hormones; immunostimulants; metabolism; and systematic hormonal preparations. It has a multi-target partnership with Etherna to research and develop mRNA-based therapies for medical dermatology. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
Prev. Close
15.466
Open
15.466
High
15.466
Low
15.466
52 wk Range
8.8711-15.47
Market Cap
3 320 M
P/E Ratio
67.2609
Shares Outstanding
215 M
Revenue
1 085 M
EPS
0.04
Dividends (Yield)
0
Beta
0.166
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Almirall S.A data using free add-ons & libraries
Get Almirall S.A Fundamental Data
Almirall S.A Fundamental data includes:
- Net Revenue: 1 085 M
- EBITDA: 211 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2022-07-24
- EPS/Forecast: 0.05
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Almirall S.A News
New
Assessing Almirall (BME:ALM) Valuation After Mixed Recent Returns And A 7.8% Undervaluation Estimate
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Almirall overview and recent share performance Almirall (BME:ALM) has drawn investo...
Almirall Announces the Approval of Seysara® in China for the Treatment of Moderate-to-Severe Acne
China’s National Medical Products Administration (NMPA) has approved Seysara® (sarecycline hydrochloride) for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris i...
Ipsen nominates Peter Guenter to its Board of Directors
Ipsen Pharma Ipsen Board of Directors Peter GuenterIpsen announced the co-optation of Peter Guenter to its Board as a Director, effective January 28, 2026.·GlobeNewswire Inc. PARIS, FRANCE, 29 Janu...
Almirall Announces "LumiNE", a Phase III Clinical Study Assessing the Efficacy of Lebrikizumab for the Treatment of Nummular Eczema
Nummular eczema is a debilitating skin condition that is distinct from atopic dermatitis but involves similar disease mechanisms including IL-13 and therefore makes targeting IL-13 with lebrikizumab a...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
